#CosmosPharmaceutical

For the third quarter of the fiscal year ending May 2026, net sales were JPY 810,380 million (7.7% YoY increase), operating income was JPY 32,021 million (1.2% YoY increase), and net income attributable to owners of parent for the quarter was JPY 22,748 million (1.8% YoY increase).

For the second quarter of the fiscal year ending May 2026, consolidated net sales were 537,175 million yen (6.2% increase YoY), operating income was 20,676 million yen (1.6% increase YoY), and net income attributable to owners of parent for the interim period was 14,648 million yen (1.5% increase YoY).

Effective February 1, 2026, the Legal Department and Hotel Department will be newly established, and the Product Development Department will be integrated into the Product Department. Personnel transfers for directors and department heads will be implemented.